Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Filings indexed 3,166 across all filing types
Latest filing 2025-05-14 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Final Dividend of Rs. 12/- Per Equity Share i.e. 600 % of the Face Value of Rs. 2/ Each Fully Paid Up for the Financial Year ended March 31, 2025.
Regulatory Filings
2025-05-14 English
Dividend
Regulatory Filings
2025-05-14 English
Outcome of Board Meeting
Regulatory Filings
2025-05-14 English
Approval of the Audited Financial Statements for the quarter and year ended March 31, 2025 and recommend the Final Dividend of Rs. 12/- per Equity Share i.e. 600 % of the Face Value of ....
Regulatory Filings
2025-05-14 English
Approval of the Audited Financial Statements for the quarter and year ended March 31, 2025 and recommend the Final Dividend of Rs. 12/- per Equity Share i.e. 600 % of the Face Value of ....
Regulatory Filings
2025-05-14 English
Press Release
Capital/Financing Update Classification · 90% confidence The document is a press release announcing the launch of Tolvaptan Tablets in the U.S. following FDA approval. It is addressed to stock exchanges and references regulatory disclosure requirements (SEBI Listing Regulations). The content focuses on product launch and exclusivity details, not on financial results, management changes, or detailed financial data. The document length is 4131 characters, which is relatively short and typical for a press release. There is no indication of financial statements, earnings data, or regulatory filings beyond the announcement itself. Therefore, this document fits best under the category of a Capital/Financing Update (CAP) as it relates to a significant business development impacting the company's market position and potential revenue streams.
2025-05-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.